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Our purpose was to determine the response rate and median and overall survival of gemcitabine as monotherapy versus gemcitabine
plus irinotecan in advanced or metastatic pancreatic cancer. Patients with histologically or cytologically confirmed adenocarcinoma
who were chemotherapy and radiotherapy naive were enrolled. Patients were centrally randomised at a one-to-one ratio to receive
either gemcitabine monotherapy (900mgm
 2 on days 1, 8 and 15 every 4 weeks (arm G), or gemcitabine (days 1 and 8) plus
irinotecan (300mgm
 2 on day 8) (arm IG), repeated every 3 weeks. The total number of cycles administered was 255 in the IG arm
and 245 in the G arm; the median number of cycles was 3. In all, 145 patients (71 in arm IG and 74 in arm G) were enrolled; 60 and
70 patients from arms IG and G, respectively, were evaluable. A complete clinical response was achieved in three (4.3%) arm G
patients; nine (15%) patients in arm IG and four (5.7%) in arm G achieved a partial response. The overall response rate was: arm IG
15% and arm G 10% (95% CI 5.96–24.04 and 95% CI 2.97–17.03, respectively; P¼0.387). The median time to tumour progression
was 2.8 months and 2.9 months and median survival time was 6.4 and 6.5 months for the IG and G arms, respectively. One-year
survival was 24.3% for the IG arm and 21.8% for the G arm. No statistically significant difference was observed comparing gemcitabine
monotherapy versus gemcitabine plus irinotecan in the treatment of advanced pancreatic cancer, with respect to overall and 1-year
survival.
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Owing to the nonspecific symptoms of the disease or to its
insidious evolution, pancreatic cancer is often diagnosed when the
disease is at an advanced stage; as a result, fewer than 20% of newly
diagnosed patients are able to have a radical excision of the
tumour (Brenna et al, 1993; Schnall and Macdonald, 1996;
Stephens, 1998). Chemotherapy is the treatment of choice in
patients with locally advanced and metastatic disease. Gemcitabine
as a single agent is considered to be the standard treatment for
these patients since, in spite of the low overall objective response,
studies have shown an improvement in overall survival and a
statistically significant clinical benefit when compared to the best
supportive care (Casper et al, 1994; Burris et al, 1997).
Other single agents have also been tested in advanced pancreatic
cancer but the response rate and survival have remained low;
moreover, the incidence of clinical benefit obtained with these
drugs has been variable (Wagener et al, 1995; Scher et al, 1996;
Androulakis et al, 1999; Rougier et al, 2000; Konstandoulakis et al,
2001; Cartwright et al, 2002). Several phase II studies have
evaluated different combinations of cytotoxic agents in order to
improve the proportion of objective responses and the duration of
survival. Numerous phase II studies have investigated combina-
tions of these active drugs with or without gemcitabine in patients
with advanced/metastatic pancreatic cancer (Rothenberg et al,
1998; Bahadori et al, 1999; Hidalgo et al, 1999; Rocha-Lima et al,
1999; Heinemann et al, 2000; Stathopoulos et al, 2001; Alberts et al,
2002; Berlin et al, 2002; Hess et al, 2003; Stathopoulos et al, 2003;
Ulrich-Pur et al, 2003). The combination of gemcitabine plus
irinotecan has resulted in an objective response of 25% with a
median overall survival ranging from 5.7 to 7 months (Rocha-Lima
et al, 2002; Stathopoulos et al, 2004). As phase II studies of
combinations of active anticancer drugs in patients with advanced/
metastatic pancreatic cancer have been associated with a better
survival (about 7 months) (Rocha-Lima et al, 2002; Stathopoulos
et al, 2003; Stathopoulos et al, 2004) compared with gemcitabine
monotherapy (about 5 months) (Miller et al, 1981), various
randomised trials are ongoing in order to validate these
observations.
Despite the fact that the achieved objective response rate with
gemcitabine-based combinations is practically similar, there are
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scontroversial results concerning overall survival; the 1-year
survival was reported to be 22% with the gemcitabine–irinotecan
combination (objective response rate (ORR) 25%) whereas overall
survival was found to be 34.8% with the gemcitabine–capecitabine
combination (ORR 18.9%) (Stathopoulos et al, 2003; Ulrich-Pur
et al, 2003).
The Gastrointestinal Working Parties of the Hellenic Oncology
Research Group (HORG) and the Hellenic Cooperative Oncology
Group (HeCOG) conducted this intergroup, multicenter, phase III
randomised trial in order to evaluate the efficacy of the
gemcitabine-irinotecan combination versus gemcitabine mono-
therapy, in previously untreated patients with inoperable locally
advanced or metastatic pancreatic cancer.
PATIENTS AND METHODS
Patients 418 years of age with histologically or cytologically
confirmed adenocarcinoma of the pancreas and bidimensionally
measurable disease, who were chemotherapy and radiotherapy
naive were enrolled in the study. Other eligibility criteria included
a World Health Organization (WHO) performance status (PS)
of 0–2, a life expectancy of at least 3 months, an adequate
bone marrow reserve (granulocyte count X1500dl
 1, platelet
count X120000dl
 1), adequate renal (serum creatinine concen-
tration o1.2mgdl
 1) and liver function (total serum bilirubin
concentration o3mgdl
 1) provided that serum transaminases
and serum proteins were normal; normal cardiac function with
no history of clinically unstable angina pectoris or myocardial
infraction or congestive heart failure within the 6 months
prior and no central nervous system involvement. Prior surgery
was allowed provided that it had taken place at least 3 weeks
before enrollment. Patients with active infection, malnutrition
or a second primary tumour (except for a nonmelanoma skin
epithelioma or in situ cervix carcinoma) were excluded from
the study. All patients gave their written informed consent to
participate in the study.
Treatment
All patients were treated on an outpatient basis. Patients were
centrally randomised by computer at a one-to-one ratio to receive
either monotherapy (arm G) with gemcitabine (Gemzar; Eli Lilly,
Indianapolis, IN, USA) at a dose of 900mgm
 2 as a 60min i.v.
infusion on days 1, 8 and 15 every 4 weeks or the combination
(arm IG) of gemcitabine (same dose on days 1 and 8) plus
irinotecan (Campto; Sanofi-Aventis Collegeville, PA, USA) on day
8 at a dose of 300mgm
 2 over a 90min i.v. infusion every 3 weeks.
Cycles were continued provided that patients had sufficiently
recovered from drug-related side effects. The allocation to either
regimen was done by stratified randomisation according to age,
performance status and stage of the disease. Standard antiemetic
treatment with ondansetron was administered to all patients.
Prophylactic recombinant human granulocyte colony-stimulating
factor (rhG-CSF; Granocyte, Sanofi-Aventis) was allowed only in
patients with Xgrade 3 granulocytopenia and given at a dose of
150mgm
 2 subcutaneously. Patients with an objective response or
stable disease received at least six chemotherapy cycles. The
protocol was approved by the Ethics and Scientific Committees of
the participating hospitals.
Dose adjustment criteria were based on haematological
parameters. Irinotecan and gemcitabine doses were reduced by
25% in cases of febrile or grade 4 neutropenia or thrombocyto-
penia. In cases of grade 3 neutropenia and/or thrombo-
cytopenia lasting for 45 days, the dose of both drugs was reduced
by 15%. Toxicities were graded according to WHO guidelines
(Miller et al, 1981).
Evaluation of patients
Pretreatment evaluation included a complete medical history and
physical examination, a full blood cell count with differential and
platelet count, a standard biochemical profile, serum carcinoem-
bryonic antigen (CEA) and CA 19-9 determinations, electrocardio-
gram, chest X-rays, ultrasound of the upper abdomen and
computed tomography scans of the chest and upper and lower
abdomen. Additional imaging studies were performed on clinical
indication; these studies were performed and analysed by the same
radiologist. Full blood cell counts with differential were performed
weekly; in cases of grade 3–4 neutropenia or grade 4 thrombo-
cytopenia, full blood cell counts with differential were evaluated
daily until the absolute granulocyte count was X1000dl
 1 and the
platelet count X75000dl
 1. A detailed medical and physical
examination was performed before each course of treatment in
order to document disease symptoms and treatment toxicity.
Biochemical tests, electrocardiogram (ECG), serum CEA and CA
19-9 determinations and chest X-rays were performed every 6
weeks. A neurological evaluation was performed by clinical
examination every 6 weeks. Lesions were measured after each
cycle if they were assessable by physical examination or by chest
X-rays; lesions assessable by ultrasound or CT scan were measured
after 3 cycles of chemotherapy.
Definition of response
A complete response (CR) was defined as the disappearance of all
measurable or evaluable disease, signs and symptoms and
biochemical changes related to the tumour for at least 4 weeks,
during which time no new lesions may appear; partial response
(PR), a450% reduction in the sum of the products of the
perpendicular diameters of all measurable lesions compared with
pretreatment measurements lasting X24 weeks, during which time
no new lesions may appear and no existing lesions may enlarge.
For hepatic lesions, a reduction of 430% in the sum of the
measured distances from a costal margin at the midclavicular line
and at the xiphoid process to the edge of the liver was required.
Stable disease (s.d.) was defined as a o50% reduction or a o25%
increase in the sum of the products of the two perpendicular
diameters of all measured lesions and the appearance of no new
lesions for 8 weeks. Progression or relapse was defined as an
increase in the product of the two perpendicular diameters of any
measurable lesion by 425% over the size present at enrolment or
for patients who responded, the size at the time of maximum
regression and the appearance of new areas of malignant disease
(usually excluding central nervous system metastases). A dete-
rioration in performance status, loss of 410% pretreatment weight
or worsening symptoms did not by themselves constitute
progression; however, persistence of these complaints or the
appearance of new symptoms required a repeat evaluation of the
extent of the disease (Donehower et al, 1995). All responses had to
be maintained for X4 weeks and had to be confirmed by an
independent panel of radiologists.
Assessment of clinical benefit
The assessment of pain was based on both the consumption of
analgesics (narcotics and non-narcotics) and the patient’s own
evaluation using a scale graded from 0 (no pain) to 10 (maximum
pain necessitating narcotics for relief). A 450% decrease of
analgesic consumption with no need for narcotics coupled with the
patient’s evaluation of a 450% decrease in pain intensity was
characterised as ‘pain improvement.’ A 450% increase in the
consumption of analgesics in combination with the patient’s
evaluation or a 450% increase in pain intensity was characterised
as ‘pain deterioration.’ All other cases were characterised as ‘no
change.’ Symptoms of vomiting and diarrhoea were assessed
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saccording to the number of daily episodes: a 50% decrease in
number was characterised as ‘improvement’ whereas a 450%
increase, as ‘deterioration.’ All other cases were characterised as ‘no
change.’ In addition, patients were asked to grade their fatigue and
anorexia using a scale of 0 (no fatigue or anorexia) to 10 (maximum
fatigue or anorexia). A 50% decrease or increase in symptom
intensity indicated ‘improvement’ or ‘deterioration,’ respectively.
Statistical analysis
The study was designed as a group-sequential clinical trial. An
interim analysis based on the O’Brien/Fleming boundary values
was performed when 50% of the endpoints had been reached
(Rocha-Lima et al, 2004). The study would have ended prema-
turely if a significant difference in survival had been observed. The
randomisation of patients into two treatment arms was performed
according to the method of random permuted blocks within strata.
Stratification factors comprised stage III or and IV disease.
Dynamic balancing was performed by the hospital. Pearson’s w
2
test (or Fisher’s exact test when appropriate) was used for the
comparisons of categorical variables. The nonparametric Mann–
Whitney test was used for comparisons of continuous variables.
Time-to-event analyses were performed where survival distribu-
tion was estimated by the Kaplan–Meier curve, and treatment
comparison was made using the log-rank test. All reported P-
values are two-sided. A P-value of o0.05 was considered
significant. The primary end point was median survival time and
the secondary end points were response rate, median time to
tumour progression and tolerance.
The randomisation was carried out at the University Hospital of
Heraklion, Crete, in the Office of Clinical Trials. There were eight
losses to follow-up (four per treatment group). The analysis of data
was done on an intention-to-treat analysis basis. The accrual time
was 36 months and the median follow-up time, 24 months.
RESULTS
Patient demographics
From November 2001 to February 2005, 145 patients (71 in the IG
arm and 74 in the G arm) were enrolled. Eleven (15.5%) IG arm
and 4 (5.4%) G arm patients were not evaluated for the following
reasons: arm IG: a PS of 3 in three patients, protocol violation in
two, consent withdrawn by six patients; arm G: renal failure in one
patient, no measurable disease in one patient, protocol violation in
one, and consent withdrawn by one patient. The patients’
characteristics are shown in Table 1. The median age was 64 years
in each arm and 78% arm IG and 86% arm G patients had stage IV
disease. Although the difference in stage IV patients enrolled in the
IG and G arms was about 8%, this difference was not statistically
significant (P¼0.272). The median number of involved organs was
2 (range, 1–4) in each arm; liver involvement was present in 34%
and 37% IG and G patients, respectively; similarly, 10 and 11%
patients enrolled in the IG and G arms, respectively, had
abdominal lymph node involvement.
Compliance with treatment
The total number of administered chemotherapy cycles were 255
(median 3; range, 1–16) for patients treated with the IG regimen
and 245 (median 3; range 1–8) for those treated with the G
regimen. The median interval between cycles was 21 (range, 21–
30.8) and 29 days (range 28–35) for the IG and G arms,
respectively. The median dose intensity was 83mgm
 2week
 1
(range, 25–100) for irinotecan and 553mgm
 2week
 1 (range,
299–600) for gemcitabine (IG arm) and 591mgm
 2week
 1
(range, 179–675) for gemcitabine (G arm). Twelve (4.7%) of the
IG arm and 13 (5.3%) of the G arm cycles were delayed. The
reasons for treatment delay were: in arm IG, haematologic toxicity
in five patients, nonhaematologic toxicity in one patient, and
nonrelated to treatment or the disease (non-neutropenic infec-
tions) in six patients; in arm G, haematologic toxicity in four
patients, nonhaematologic toxicity in two patients and nonrelated
to treatment or the disease in six patients. Dose reduction was
required in eight (13.3%) patients treated with IG and 17 (24.3%)
patients treated with G (Po0.001). Dose reduction was required in
34 (13.3%) of the IG arm and 60 (24.5%) of the G arm cycles.
Haematologic toxicity was the main reason for dose reduction in
both groups; however, the incidence of haematologic toxicity was
higher (35.3%) in patients treated with IG than in those treated
with G (26.7%) (Po0.001) Table 2. In addition, the incidence of no
drug administration on day 8 and/or day 15 was higher (46.7%) in
patients enrolled in the G arm versus 29.4% in the IG arm
(P¼0.002). Treatment was completed as per protocol in 18 (30%)
IG arm patients and in 12 (17.1%) G arm patients whereas it was
Table 1 Patients’ characteristics
Treatment groups
IG (n¼60) G (n¼70)
n (%) n (%)
Age (year)
Median (range) 64 (31–84) 64 (44–83)
Gender
Male 39 (65) 42 (60)
Female 21 (35) 28 (40)
Performance status (WHO)
0–1 52 (87) 60 (86)
2 8 (13) 10 (14)
Stage
III 13 (22) 10 (14)
IV 47 (78) 60 (86)
(P¼0.272)
No. of organs involved
1 24 (40) 24 (34)
2 22 (37) 34 (49)
43 14 (23) 12 (17)
Prior Surgery 11 (18) 16 (23)
No prior treatment 49 (82) 54 (77)
Table 2 Reasons for dose reduction
Treatment groups
IG (255 cycles) G (245 cycles)
n (%) n (%)
Dose reduction 34 (13.3) 60 (24.5)
Due to:
Haematologic toxicity 12 (35.3)* 16 (26.7)
Nonhaematologic toxicity 10 (29.4) 8 (13.3)
Haematologic and nonhaematologic
toxicity
1 (2.9) 1 (1.7)
Day 8 and/or day 15 treatment not
given (for reasons other than toxicity)
10 (29.4) 28 (46.7)
w
Other 1 (2.9) 7 (11.7)
*Po0.001.
wP 0.002.
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patients and in 49 (70.%) G arm (P¼0.027).
The total number of deaths at the end of the study were 46
(76.7%) and 57 (81.4%) patients enrolled in the IG and G arms,
respectively. Death was due to malignant disease in 84.8% and
84.2% of the G and IG patients, respectively. One patient in arm G
died because of stroke.
Response to treatment
Responses were analysed on an intention-to-treat basis. There
were no complete responses in the IG-arm patients; however, a
complete clinical response was achieved in three (4.3%) patients
treated with G. In addition, nine (15%) IG arm and four (5.7%) G
arm patients achieved a partial response (overall response rate: IG
arm, 15% and G arm 10%, 95% CI 5.96–24.04% and 2.97–17.03,
respectively; P¼0.387). Stable disease was achieved in 16 (26.7%)
IG arm and 13 (18.6%) G arm patients, while disease progression
was observed in 35 (58.3%) and 50 (71.4%) of the IG and G arm
patients, respectively. Tumour disease control (CRþPRþSD) was
achieved in 25 (41.7%; 95% CI: 29.19–54.14) and in 20 (28.6%;
95% CI 17.99–39.15) patients treated with IG and G, respectively,
(P¼0.800). The median time to tumour progression (TTP) was 2.8
months (range 1.0–17.3 months) and 2.9 months (range 1.0–17.4
months) for patients treated with IG and G, respectively
(P¼0.795).
After a median follow-up period 5.9 months (range, 1.0–24.4
months) for IG arm patients and 5.3 months (range, 1.0–27.4) for
G arm patients, 46 (76.7%) and 57 (81.4%) patients, respectively,
died. The median survival time was 6.4 months (range, 1.0–24.4
months) and 6.5 months (range, 1.0–27.4 months) in patients
treated with IG and G, respectively (P¼0.970). The 1-year survival
was 24.3% in patients treated with IG and 21.8% in patients treated
with G (Figure 1). In all, 21 (35%) in the IG and 22 (31.4%) in the G
group received second-line chemotherapy. The difference was not
statistically significant (P¼0.666) with regard to survival benefit.
Effect of treatment on serum levels of CA 19-9
In 52 (86.7%) and 60 (85.7%) patients treated with the IG and G
regimens, respectively, there were sufficient evaluable data on the
serum levels of CA 19-9. In 24 (46.2%) IG arm and in 22 (36.7%) G
arm patients, a 425% decrease of serum levels of CA 19-9 was
observed (P¼0.308). Similarly, 13 (25%) and 23 (38.3%) patients
treated with the IG and G regimens, respectively, showed a 425%
increase in the serum levels of CA 19-9 during treatment. There
was no clear correlation between CA 19-9 measurements and
radiological response (P¼0.226).
Effect of treatment on tumour-related symptoms
Tumour-related symptoms were present at enrolment in 48 (80%)
and 58 (82.9%) of patients treated with IG and G, respectively.
There was no significant difference between the two chemotherapy
regimens with regard to their effect on tumour-related symptoms.
Toxicity
Table 3 shows the incidence of severe (grade 3 and 4) haematologic
and non-haematologic toxicity associated with the IG and G
regimens. Grade 3 and 4 neutropenia occurred in 16 (26.7%)
patients treated with IG and 11 (15.7%) patients treated with G
(P¼0.125). No patients developed febrile neutropenia. Grade 3
and 4 thrombocytopenia occurred in three (5.0%) patients treated
with IG (P¼0.028). Nonhaematologic toxicity was mild, usually
o5%, regardless of the chemotherapy regimen administered.
DISCUSSION
Locally advanced or metastatic pancreatic cancer is an incurable
disease and in this setting, only systemic chemotherapy may result
in a small improvement in survival and clinical benefit. In an effort
to improve the results obtained with gemcitabine, which is the
standard treatment, several phase II studies have evaluated it in
combination with other cytotoxic agents. Some of these studies
have reported an improved median overall survival and 1-year
survival rates. However, the question which concerns the super-
iority of gemcitabine-based chemotherapy regimens over gemci-
tabine monotherapy in terms of overall survival and quality of life
can only be answered by comparative randomised studies.
The present study was based on the promising results of a
previous phase II trial of irinotecan and gemcitabine in patients
with advanced/metastatic pancreatic cancer, which reported an
objective response rate of 25% (Stathopoulos et al, 2003). This
efficacy of the irinotecan-gemcitabine combination was higher
than that obtained with gemcitabine alone. Similar results have
also been reported with the irinotecan-gemcitabine regimen by
another research group (Rocha-Lima et al, 2002). The results of the
present study demonstrate that although the ORR was higher with
the IG regimen compared with that of the G regimen, this
difference did not reach statistical significance. Moreover, there
was no difference between the two treatment arms in terms of
duration of response, TTP, overall survival and 1-year survival.
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Figure 1 Kaplan–Meier overall survival.
Table 3 Severe (grade 3 and 4) haematologic and nonhaematologic
toxicity
Grade 3 and 4 (WHO)
IG G
n¼60 n¼70
n (%) n (%) P-value
Anemia 3 (5) 3 (4.3) NS
Neutropenia 16 (26.7) 11 (15.7) 0.125
Thrombocytopenia 3 (5) — 0.028
Nausea 1 (1.7) 2 (2.9) NS
Vomiting 1 (1.7) 1 (1.4) NS
Diarrhea 2 (3.3) 2 (2.9) NS
Asthenia — 4 (5.7) —
Influenza-like syndrome 2 (3.3) —
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gemcitabine combination with gemcitabine alone in patients with
locally advanced and metastatic pancreatic cancer have recently
been reported (Rocha-Lima et al, 2004). This study demonstrated a
significantly higher ORR of 16.1% with the combination versus
that achieved with gemcitabine alone (ORR 4.4%); moreover, the
ORR was also higher with the two-drug combination (25.9%)
compared with gemcitabine monotherapy (ORR 4.2%). In addi-
tion, these authors (Rocha-Lima et al, 2004) reported that the TTP
was significantly higher in patients with locally advanced disease
treated with the irinotecan–gemcitabine combination compared
with gemcitabine as a single agent. However, there was no
difference between the two chemotherapy regimens in terms of
overall and 1-year survival (Rocha-Lima et al, 2004). It is
interesting to note that the above study (Rocha-Lima et al, 2004)
and the present trial have documented a similar efficacy achieved
with the irinotecan–gemcitabine combination; however, gemcita-
bine monotherapy resulted in a relatively low response rate
(Rocha-Lima et al, 2004) which may account for the observed
statistical difference.
These results were obtained with an acceptable toxicity profile
for both regimens. Indeed, the incidence of severe grade 3 and 4
toxicity was practically similar in the two arms and only the
incidence of severe thrombocytopenia was shown to be statistically
higher in the combination arm compared with gemcitabine
monotherapy. In addition, the incidence of severe asthenia was
higher in the monotherapy arm compared to the combination arm.
It is difficult to explain why the combinations of gemcitabine
with a second anticancer drug cannot significantly improve the
overall survival of patients with locally advanced/metastatic
pancreatic cancer. This may reflect the natural history of
the tumour, which is characterised by its indolent onset and
its inoperability at the time of diagnosis. The clinical character-
istics of this disease are directly related to the biology of the
tumour cell. Therapeutic approaches which target the specific
biologic mechanisms involved in tumour cell proliferation and
metastasis might be revealed to be more effective in these patients.
The recently reported improvement of overall survival in patients
with advanced and metastatic pancreatic cancer with the
gemcitabine–erlotinib combination compared to single-agent
gemcitabine supports this hypothesis (Moore et al, 2005).
Additional studies evaluating novel agents against specific
molecular targets alone or in combination with other cytotoxic
agents are necessary.
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